Almirall Stock - Weekly outlook with upcoming H1 results and pipeline milestones

Edited by ad hoc news Earnings & Calendar Desk. Verified prior to publication on 06/22/2026, 10:33 CET. Details in the imprint.

Almirall (ES0157097017) begins the new week with investors watching the timetable for its first-half 2026 earnings and the progress of its late-stage dermatology pipeline. With no fresh ad-hoc release, the focus shifts to the company’s calendar and expected catalysts according to recent consensus data.

What the upcoming weeks bring

Almirall’s financial calendar on its investor relations website shows a regular pattern of half-year reporting in late July or early August, but a precise date for H1 2026 is not yet officially posted as of today. The company confirms its commitment to timely disclosure in its latest annual report.

For 2025, Almirall reported first-half figures in late July, combining financial data with an update on its dermatology pipeline and launches in psoriasis and atopic dermatitis. The upcoming H1 2026 release is therefore expected to again pair numbers with R&D and commercial updates, which typically drive sentiment in the stock around reporting dates.

Consensus expectations and calendar focus

Market data providers summarizing analyst estimates see Almirall as a focused European dermatology player, with consensus pointing to mid-single-digit revenue growth in 2026, supported by recent launches and geographic expansion. Several houses maintain Neutral to Buy stances, with price targets clustering moderately above the current quote.

Against this backdrop, the upcoming half-year report and any guidance commentary are central to whether analysts adjust their models for 2026 and 2027. On balance, the weekly outlook for the stock is driven less by macro factors and more by the company’s ability to execute on its dermatology strategy and to provide clarity on regulatory milestones.

How the company makes money

Almirall generates most of its revenue from prescription dermatology medicines, including treatments for psoriasis, atopic dermatitis, and other chronic skin conditions. The company combines in-house R&D with in-licensing and partnerships to build a portfolio focused on European and selected international markets.

Where the stock trades today

Almirall shares (ES0157097017) trade on the Spanish stock market in Madrid; the latest reliably available quote shows the stock around the mid-single-digit euro range, with intraday prices and exact market capitalization updated on the exchange’s website as of the most recent trading session.

This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.